Abstract：
To address the limitations of conventional sentinel lymph node biopsy (SLNB), a novel hybrid tracer (indocyanine green [ICG]-99mTc-nanocolloid) has been developed. This meta-analysis aimed to compare the differences between the novel hybrid tracer and conventional methods using ICG or radioisotope (RI) for SLNB in head and neck malignancies. This study was registered in the International Prospective Register of Systematic Reviews (CRD42023409127). PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched. This study included raw data on the number of sentinel lymph nodes (SLNs) identified using different modalities during surgery for head and neck malignancies. The identification rate of SLNs was the main outcome of interest. Prognostic data and complication rate cannot be deduced from this article. The heterogeneity test (I2) determined the use of a fixed- or random-effects model for the pooled risk ratio (RR). Overall, 1275 studies were screened, of which 11 met the inclusion criteria for the meta-analysis. In SLN identification of head and neck malignancies, ICG-99mTc-nanocolloid was superior to ICG or RI. In the subgroup analyses, the detection rates of ICG and RI tracers in SLNB were comparable, regardless of the device, tumor type, or tumor stage. In conclusion, in SLN identification of head and neck malignancies, the use of ICG-99mTc-nanocolloid is superior to the single technique of ICG or RI. This study suggests that Hospitals using ICG or RI may find it beneficial to change their practice to ICG-99mTc-nanocolloid, especially in the head and neck area, owing to its superior effectiveness.
摘要：
为了解决常规前哨淋巴结活检（SLNB）的局限性，已开发出一种新型的混合示踪剂（吲哚菁绿[ICG]-99mTc-纳米胶体）。这项荟萃分析旨在比较新型混合示踪剂与使用ICG或放射性同位素（RI）治疗头颈部恶性肿瘤SLNB的常规方法之间的差异。本研究已在国际前瞻性系统评价登记册（CRD42023409127）中注册。PubMed,Embase,WebofScience,对Cochrane图书馆进行了系统搜索。这项研究包括在头颈部恶性肿瘤手术期间使用不同方式识别的前哨淋巴结（SLN）数量的原始数据。SLN的识别率是感兴趣的主要结果。无法从本文中推导出预后数据和并发症发生率。异质性检验（I2）确定了混合风险比（RR）的固定或随机效应模型的使用。总的来说,筛选了1275项研究，其中11人符合荟萃分析的纳入标准.在SLN识别头颈部恶性肿瘤中，ICG-99mTc-纳米胶体优于ICG或RI。在亚组分析中，SLNB中ICG和RI示踪剂的检出率相当，不管是什么设备，肿瘤类型,或肿瘤分期。总之,在SLN识别头颈部恶性肿瘤中，ICG-99mTc-纳米胶体的使用优于ICG或RI的单一技术。这项研究表明，使用ICG或RI的医院可能会发现将其实践更改为ICG-99mTc-nanocolloid是有益的，尤其是在头部和颈部，由于其优越的效力。
